✦ LIBER ✦

590 Soluble immunological parameters in patients treated with interleukin-2 (IL-2) plus interferon-α (IFN)

✍ Scribed by Meri-Sisko Vuoristo; Pirkko Kellokumpu-Lehtinen

Book ID: 116167341
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 150 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)95844-v

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Metastatic renal-cell carcinoma patients

Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon γ: Immunological monitoring

✍ Françoisc Farace; Marc Pallardy; Eric Angevin; Thierry Hercend; Bernard Escudier 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 737 KB

## Abstract We investigated the biological response of 73 patients with metastatic renal‐cell carcinoma (MRCC) treated by repetitive weekly cycles of high‐dose interleukin 2 (IL‐2) (protocol 1, 40 patients) or IL‐2 plus interferon‐gamma (IFN‐γ) (protocol 2, 33 patients). The objectives of this stud

Adopive immunotherapy with interleukin-2

Adopive immunotherapy with interleukin-2 (IL2) + interferon (αIFN) + IL2-activated lymphocytes (LAK) in metastatic renal cell cancer

✍ Goey, S.H.; Kruit, W.H.J.; Eggermont, A.M.M.; Bolhuis, R.L.H.; Stoter, G. 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 166 KB

Slow-release lanreotide plus interferon-

Slow-release lanreotide plus interferon-α-2b (IFN-α-2b) relieves symptoms in patients with advanced medullary thyroid cancer,

📂 Article 📅 2000 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Clinical experience with the combined us

Clinical experience with the combined use of recombinant interleukin-2 (IL2) and interferon alfa-2a (IFNα) in metastatic melanoma

✍ W. H. J. Kruit; S. H. Goey; J. R. T. Monson; R. A. Stahel; F. Calabresi; R. Mert 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB

150 - Subcutaneous (SC) interleukin-2 (I

150 - Subcutaneous (SC) interleukin-2 (IL-2) plus alpha interferon (IFN-α) and 5 fluorouracil (5 FU) in out-patients (pts) with metastatic renal cell carcinoma (MRCC). Scapp II trial

✍ J.M. Tourani; A. Benhammouda; P. Guillet; C. Pfister; B. Paule; J.F. Berbah; Y. 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 262 KB

Prognostic factors for survival in patie

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-α

✍ Luciano Canobbio; Alessandra Rubagotti; Loredana Miglietta; Daniela Cannata; Ant 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 356 KB